Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cencora ( (COR) ) has shared an update.
Cencora has completed the acquisition of Retina Consultants of America, acquiring an 85% interest in the company for $4.4 billion. This acquisition strengthens Cencora’s leadership in specialty medical services, expands its management services offerings, and is expected to enhance value for physicians and patients. Following the acquisition, Cencora raised its adjusted diluted earnings per share guidance for fiscal year 2025, reflecting anticipated benefits from the acquisition and continued momentum in its U.S. Healthcare Solutions segment.
More about Cencora
Cencora is a leading global pharmaceutical solutions organization focused on improving health outcomes for people and animals worldwide. The company collaborates with pharmaceutical innovators to enhance market access to therapies and ensures the reliable delivery of pharmaceuticals and healthcare solutions. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500, with annual revenue exceeding $290 billion.
Average Trading Volume: 1,252,649
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $43.43B
See more data about COR stock on TipRanks’ Stock Analysis page.
